홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.1
  1. 홈
  2. /화합물

알로프레난-3ALPHA-OL-20-ONE

Allopregnanolone

HCID 92786
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
516-54-1
표준 SMILES
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
InChIKey
AURFZBICLPNKBZ-SYBPFIFISA-N
분자식
C21H34O2
평균 분자량
318.5 g/mol
단동위원소 질량
318.25588033

개요

Brexanolone is a 3-hydroxy-5alpha-pregnan-20-one in which the hydroxy group at position 3 has alpha-configuration. It is a metabolite of the sex hormone progesterone and used for the treatment of postpartum depression in women. It has a role as an antidepressant, a sedative, an intravenous anaesthetic, a GABA modulator and a human metabolite.

이름 및 식별자

우선 이름
Allopregnanolone
IUPAC
1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
현지명
알로프레난-3ALPHA-OL-20-ONE
영어명
Allopregnanolone
분자식
C21H34O2
분자량
318.49

이름 및 동의어

Allopregnanolone516-54-1BrexanoloneAllotetrahydroprogesteroneAllopregnan-3alpha-ol-20-one3alpha-hydroxy-5alpha-pregnan-20-one3alpha,5alpha-THPbrexanolona3alpha-OH DHP3alpha-Hydroxy-5alpha-dihydroprogesteroneS39XZ5QV8YCHEMBL207538
이름 더 보기
알로프레난-3ALPHA-OL-20-ONEAnlotinib Dihydrochloride(3a)-Allopregnanolone3α-hydroxy-5α-pregnan-20-one1-((3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethan-1-one(3alpha)-Allopregnanolone3α-hydroxy-5α-pregnan-20-oneAllopregnanolone(Brexanolone)5α-P
CHEBI:50169DEA NO. 2400DTXSID901016239Pregnan-20-one, 3-hydroxy-, (3-alpha,5-alpha)-3 alpha Hydroxy 5 alpha pregnan 20 one3 alpha-Hydroxy-5 alpha-pregnan-20-onealpha-Hydroxy-5 alpha-pregnan-20-one, 3alpha-pregnan-20-one, 3 alpha-Hydroxy-5

물성

구조 계산 물성보충 중

XLogP
4.9
극성 표면적
37.3 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
2
회전 가능 결합 수
1
무거운 원자 수
23
형식 전하
0
복잡도
500

실험 및 물리화학적 성질

Drugs · 2건

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Listed in ZINC15

LipidsLipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives [ST0203]
Human Drugs · 3건

Breastfeeding; Lactation; Milk, Human; Antidepressants; Antidepressive Agents; GABA Agents; Hormones; Progesterone Congeners

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point177 °C
Physical DescriptionSolid
Collision Cross Section177.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점
176 · 176-178°
끓는 점
431.2 · 431.2±18.0 °C(Predicted)
밀도
1.053 · 1.053±0.06 g/cm3(Predicted)
저장 조건
Store at RT
용해도

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS ClassificationNot Classified

유해성 정보

Regulatory InformationDEA schedule IV controlled substance
Hazard Classes and CategoriesNot Classified

독성 정보

HepatotoxicityIn premarketing studies, liver test abnormalities were uncommon in patients receiving brexanolone (
Adverse EffectsClinical trials have demonstrated brexanolone as generally well-tolerated. The most common adverse effects associated with brexanolone are dizziness, sedation/somnolence, xerostomia, loss of consciousness, and hot flushes.
Toxicity Summary · 1건

Brexanolone has a rapid onset of action within 60 hours of infusion and has a sustained response for up to 30 days after infusion. Patients in clinical trials were not followed after a 30-day follow-up period, limiting data on toxicity from long-term use. Long-term efficacy of brexanolone, when compared with other antidepressants, is unknown and needs further research.

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Brexanolone

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

화학 및 산업

약리 정보

ATC Code · 2건

N - Nervous system

QN - Nervous system

Protein BindingThe plasma protein binding recorded for brexanolone is greater than 99% and was determined to be independent of plasma concentrations.
Pharmacodynamics · 1건

Brexanolone potentiated GABA-mediated currents from recombinant human GABA(a) receptors in mammalian cells expressing α1β2γ2 receptor subunits, α4β3δ receptor subunits, and α6β3δ receptor subunits. Moreover, it was determined during a Phase 1 randomized, placebo and positive-controlled, double-blind, three-period crossover thorough QT study in 30 healthy adult subjects that brexanolone use did not prolong the QT interval to any clinically relevant extent when administered at 1.9-times the exposure occurring at the highest recommended infusion rate (90 mcg/kg/hour).

Mechanism of Action · 1건

Brexanolone is a neuroactive steroid that occurs naturally (referred to as natural allopregnanolone) in the body when the female sex hormone progesterone is metabolized. This steroid compound is also believed to exhibit activity as a barbiturate-like, positive allosteric modulator of both synaptic and extrasynaptic GABA(a) receptors. In doing so, brexanolone can enhance the activity of GABA at such receptors by having GABA(a) receptor calcium channels open more often and for longer periods of time. Furthermore, it is believed that brexanolone elicits such action on GABA(a) receptors at a binding site that is distinct from those associated with benzodiazepines. Concurrently, GABA is considered the principal inhibitory neurotransmitter in the human body. When GABA binds to GABA(a) receptors found in neuron synapses, chloride ions are conducted across neuron cell membranes via an ion channel in the receptors. With enough chloride ions conducted, the local, associated neuron membrane potentials are hyperpolarized - making it more difficult or less likely for action potentials to fire, ultimately resulting in less excitation of the neurons, like those involved in neuronal pathways that may be in part responsible for eliciting certain traits of PPD like stress, anxiety, etc. Postpartum depression (PPD) is a mood disorder that can affect women after childbirth. Women with PPD experience feelings of extreme sadness, anxiety, and exhaustion that can make it difficult or even dangerous for them to perform various daily activities or care for themselves or for others, including newborn. Although the exact pathophysiology of PPD remains unknown, it is believed that altered profiles and rapid, unpredictable fluctuations in the blood concentrations of neuroactive steroids like endogenous brexanolone (among others), GABA, and GABA receptors occur in women who are at risk of PPD after childbirth. In particular, within the context of PPD, it is proposed that endogenous brexanolone levels can quickly drop or fluctuate variedly after childbirth and that GABA(a) receptor levels and expression are decreased and down-regulated throughout pregnancy. Such fluctuations and decreases may consequently leave women susceptible to the possibility of PPD. As a medication, synthetic brexanolone can subsequently facilitate a return of positive allosteric modulator GABA(a) modulation while GABA(a) receptor levels and expression gradually return to normal in the time following postpartum. As such, studies suggest the potential for the development of brexanolone as a new mechanism for treatment of PPD that is directly related to the underlying pathophysiology as opposed to many other antidepressant medications whose pharmacological actions are usually entirely unrelated.

관련 반응

18건
반응 기록 만들기
HRID 232793 반응식
HRID 232793반응물로uspto-grants-1997_01
HRID 232797 반응식
HRID 232797생성물로uspto-grants-1997_01
HRID 232798 반응식
HRID 232798반응물로uspto-grants-1997_01
HRID 232799 반응식
HRID 232799반응물로uspto-grants-1997_01
HRID 232803 반응식
HRID 232803반응물로uspto-grants-1997_01
HRID 232804 반응식
HRID 232804반응물로uspto-grants-1997_01
HRID 232808 반응식
HRID 232808반응물로uspto-grants-1997_01
HRID 247813 반응식
HRID 247813생성물로uspto-grants-1993_05
이전1 / 3 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

데이터베이스 식별자

CAS
516-54-1
PubChem CID
92786
DTXSID
DTXSID901016239
ChEMBL
CHEMBL207538
ChEBI
CHEBI:50169
UNII
S39XZ5QV8Y
EC Number
869-372-7
Nikkaji
J6.315K
20 mg/mL, · 클로로포름: 20 mg/mL, 투명, 무색
물리적 상태
흰색 고체
산도 계수 (pKa)
15.12 · 15.12±0.70(Predicted)
색상
하얀색
Merck
13 · 13,272
BRN
3211363 · 3211363
안정성
2 · 공급된 상태로 2년 동안 안정적입니다. DMSO 또는 에탄올 용액은 -20°에서 최대 1개월 동안 보관할 수 있습니다.
InChI
InChI=1/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/s3
InChIKey
AURFZBICLPNKBZ-SYBPFIFISA-N
SMILES
[C@]12([H])CC[C@]3(C)[C@H](CC[C@@]3([H])[C@]1([H])CC[C@@]1([H])C[C@H](O)CC[C@]21C)C(=O)C |&1:0,4,6,9,11,15,18,22,r|
wgk
3
rtecs
TU4383000
HS 번호
2937900090
safety_code
22-24/25
F 고인화성물질
10
Biological Half-LifeThe terminal half-life observed for brexanolone is approximately 9 hours.
Metabolism/Metabolites · 1건

Brexanolone is extensively metabolized by non-cytochrome (CYP) based pathways by way of three main routes - keto-reduction (via aldo-keto reductases), glucuronidation (via UDP-glucuronosyltransferases), and sulfation (via sulfotransferases). Three predominant circulating metabolites result from such metabolic pathways and they are all pharmacologically inactive and ultimately do not contribute to the overall efficacy of the medication.

FDA Pharmacological Classification · 5건

S39XZ5QV8Y

BREXANOLONE

Established Pharmacologic Class [EPC] - Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator

Mechanisms of Action [MoA] - GABA A Receptor Positive Modulators

Brexanolone is a Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator. The mechanism of action of brexanolone is as a GABA A Receptor Positive Modulator.

MeSH Pharmacological Classification · 3건

Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site.

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.

Endogenous compounds or drugs that affect neuronal excitability through modulation of specific ionotropic receptors (e.g., GABA-A RECEPTORS). Endogenous neurosteroids are steroid hormones de novo synthesized by neurons and glial cells from steroid metabolite precursors (e.g., PREGNENOLONE).

Absorption, Distribution and Excretion · 4건

It has been determined that brexanolone has a low oral bioavailability of approximately <5% in adults, which suggests infant exposure would also be expected to be low.

Following the administration of radiolabeled brexanolone, it was observed that 47% of the administrated dose was recovered largely as metabolites in the feces and 42% in urine, where less than 1% as recovered as unchanged brexanolone.

The volume of distribution documented for brexanolone is approximately 3 L/kg, a value which suggests relatively extensive distribution into tissues.

The total plasma clearance determined for brexanolone is approximately 1 L/h/kg.

Cellular LocationsExtracellular
응용 분야 · 2건

개요Allopregnanolone is an endogenous inhibitory pregnane neurosteroid that is synthesized from progesterone . It acts as a positive allosteric modulator of GABAA receptors at nM concentrations (exhibiting the greatest potentiation at isoforms containing δ subunits) and of GABAC receptors at μM concentrations. Allopregnanolone displays effects similar to other GABAA receptor potentiators such as benzodiazepines, including potent anticonvulsant, anxiolytic, and sedative activity.

용도(3α)-Allopregnanolone acts as a GABAA receptor positive allosteric modulator. (3α)-Allopregnanolone is a metabolite of Progesterone (P755900). (3α)-Allopregnanolone is a neuroactive steroid present in the blood and also the brain.